Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Sayed et al

J Immunother Cancer. 2024 Apr 22;12(4):e009137. doi: 10.1136/jitc-2024-009137.

Yoshihiro Noguchi¹, Miao Yan^{2

3

4}, Tomoya Tachi⁵, Tomoaki Yoshimura⁶

¹ Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Gifu, Japan noguchiy@gifu-pu.ac.jp.
² Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
³ International Research Center for Precision Medicine, Transformative Technology and Software Services, Changsha, Hunan Province, China.
⁴ Toxicology Counseling Center of Hunan Province (TCCH), Changsha, Hunan Province, China.
⁵ Department of Clinical Pharmacy, Nagoya City University, Nagoya, Aichi, Japan.
⁶ Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Gifu, Japan.

No abstract available

Keywords: Cardiotoxicity; T cell; Treatment related adverse event - trAE.

Publication types